Display options
Cite
Mehta HB, Wang L, Malagaris I, et al. More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. J Clin Epidemiol. 2021;137:113-125doi: 10.1016/j.jclinepi.2021.03.029.
Mehta, H. B., Wang, L., Malagaris, I., Duan, Y., Rosman, L., & Alexander, G. C. (2021). More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. Journal of clinical epidemiology, 137113-125. https://doi.org/10.1016/j.jclinepi.2021.03.029
Mehta, Hemalkumar B, et al. "More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review." Journal of clinical epidemiology vol. 137 (2021): 113-125. doi: https://doi.org/10.1016/j.jclinepi.2021.03.029
Mehta HB, Wang L, Malagaris I, Duan Y, Rosman L, Alexander GC. More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. J Clin Epidemiol. 2021 Sep;137:113-125. doi: 10.1016/j.jclinepi.2021.03.029. Epub 2021 Apr 07. PMID: 33838274.
Copy Download .nbib Format: NLM
Share it on

J Clin Epidemiol. 2021 Sep;137:113-125. doi: 10.1016/j.jclinepi.2021.03.029. Epub 2021 Apr 07.

More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review.

Journal of clinical epidemiology

Hemalkumar B Mehta, Lin Wang, Ioannis Malagaris, Yanjun Duan, Lori Rosman, G Caleb Alexander

Affiliations

  1. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: [email protected].
  2. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  3. Department of Medicine, The University of Texas Medical Branch, Galveston, TX, USA.
  4. Welch Medical Library, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
  5. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 33838274 DOI: 10.1016/j.jclinepi.2021.03.029

Abstract

OBJECTIVE: While several prescription drug-based risk indices have been developed, their design, performance, and application has not previously been synthesized.

STUDY DESIGN AND SETTING: We searched Ovid MEDLINE, CINAHL and Embase from inception through March 3, 2020 and included studies that developed or updated a prescription drug-based risk index. Two reviewers independently performed screening and extracted information on data source, study population, cohort sizes, outcomes, study methodology and performance. Predictive performance was evaluated using C statistics for binary outcomes and R

RESULTS: Of 19,112 articles that were retrieved, 124 were full-text screened and 25 were included, each of which represented a de novo or updated drug-based index. The indices were customized to varied age groups and clinical populations and most commonly evaluated outcomes including mortality (36%), hospitalization (24%) and healthcare costs (24%). C statistics ranged from 0.62 to 0.92 for mortality and 0.59 to 0.72 for hospitalization, while adjusted R

CONCLUSIONS: More than two-dozen prescription drug-based risk indices have been developed and they differ significantly in design, performance and application.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: Administrative healthcare data; Comorbidity scores; Pharmacy data; Prescription drugs; Risk index; Systematic review

Substances

MeSH terms

Publication Types